← Eichor
Condition: Angioimmunoblastic T Cell Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Angioimmunoblastic T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07058103A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07278856Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Phase 3 · 1 location(s) · Fudan University · NCT07300514Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07055477A Study of Enasidenib in People With T-Cell Lymphoma
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06756308Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AIT
Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07168317A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma W
Phase 3 · 44 location(s) · SecuraBio · NCT06522737Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With P
Phase 3 · 158 location(s) · Eastern Cooperative Oncology Group · NCT06724237
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.